Stock info Incyte Corp | Filter  Basic-Info

Incyte Corp

The past year was a relatively good year for Incyte Corp investors

Over the last 12 months, that were loss-making period for the investors in Incyte Corp, the stock lost around 7 percent. Over the past 5 years Incyte Corp' stock rose at around 668 percent in value. Incyte Corp's revenues between 2011 and 2015 were very volatile through the time and moved between 297,06 million dollars and 753,75 million dollars. Incyte Corp's net results between 2011 and 2015 were very fluctuating and moved between -186,54 million dollars and 6,53 million dollars.

Incyte Corp's core business is the pharmaceutical sector. Between 2006 and 2016 the global pharmaceutical companies gained around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.

The American company didn't pay out any dividends (in the past 5 years).

Incyte Corp' balance mostly financed with equity

At the end of 2015 the pharmaceutical company's balance sheet equaled 1,01 billion dollars. Last year the total debt of the company was 836,28 million dollars. This equals around 83,01 percent of the total balance sheet. As per the end of 2015 Incyte Corp's price/earnings-ratio equaled 1219. So investors paid for 1 stock 1219 times the earnings per share of 2015. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a growth stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 18,77 billion dollars. At the end of 2015 around 179,6 million stocks were listed.

At this page you find all Incyte Corp's financial reports. More information about Incyte Corp can be found it's website. .